Wednesday, February 18, 2026 The IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer trial has permanently closed.This study sought to answer if the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment and if there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker. As well as to find out if this approach is better or worse than the usual approach for this type of cancer. For more information please visit the CCTG IND243 members trial pagePlease see the closure notice for additional details.
